Sana Biotechnology SANA Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's accrued expenses and other liabilities?
- Sana Biotechnology (SANA) reported accrued expenses and other liabilities of $8.12M in Q1 2026.
- How has Sana Biotechnology's accrued expenses and other liabilities changed year-over-year?
- Sana Biotechnology's accrued expenses and other liabilities decreased by 17.2% year-over-year, from $9.81M to $8.12M.
- What is the long-term trend for Sana Biotechnology's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Sana Biotechnology's accrued expenses and other liabilities has grown at a -1.7% compound annual growth rate (CAGR), from $9.47M to $8.68M.